{"product_id":"huons-swot-analysis","title":"Huons SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHuon’s strengths include a strong regional brand and vertical integration in aquaculture, while weaknesses like capital intensity and disease risk constrain margins; opportunities lie in export expansion and value-added products, but regulatory shifts and environmental pressures pose real threats—purchase the full SWOT analysis to access a detailed, editable report and Excel matrix that support investment, strategic planning, and due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Healthcare Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuons holds a balanced revenue mix: pharmaceuticals ~42%, medical devices ~25%, aesthetics ~18%, and health functional foods ~15% in FY2025, which reduced single‑sector exposure and kept consolidated revenue growth at 9.8% YoY to KRW 1.12 trillion by Dec 31, 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Ophthalmology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphuons holds about share of south korea eye drop market in driven by a broad mix rx and otc products annual ophthalmic sales krw billion. its dedicated single-dose production line cuts unit costs versus multi-dose batches supports iso quality yields above r spend was billion focused on chronic conditions like dry sustaining pipeline with three phase ii candidates.\u003e\n\u003c\/phuons\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Aesthetics and Wellness Division\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHuons leverages strong brand power in aesthetics—notably botulinum toxins and dermal fillers—driving segment revenue that accounted for about 28% of group sales in 2024 (KRW 312 billion of KRW 1.12 trillion). The integrated cosmeceuticals and wellness line meets rising anti‑aging demand, with category growth ~9% CAGR 2020–2024. This high-margin division (operating margin ~24% in 2024) remains a core profit pillar and cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced CMO and CDMO Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuons operates state-of-the-art CMO\/CDMO facilities serving domestic and export clients, driving production-asset utilization above 85% in 2024 and supporting KRW 210bn contract-revenue (FY 2024).\u003c\/p\u003e\n\u003cp\u003eLong-term partnerships yield predictable cash flow—CMO backlog covered ~18 months of output in Dec 2024—and global GMP\/ICH compliance positions Huons for complex formulations and higher-margin work.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e85%+ utilization (2024)\u003c\/li\u003e\n\u003cli\u003eKRW 210bn contract revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003e18-month CMO backlog (Dec 2024)\u003c\/li\u003e\n\u003cli\u003eGMP\/ICH-compliant, complex formulations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Domestic Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuons has a nationwide distribution network covering over 2,000 hospitals, 5,500 clinics, and 15,000 pharmacies in South Korea, enabling product launches to reach key accounts within 4–6 weeks.\u003c\/p\u003e\n\u003cp\u003eThis deep reach sustains strong brand loyalty among healthcare professionals, contributing to Huons’ 2024 domestic pharma sales share of ~6.8% and steady annual channel retention above 92%.\u003c\/p\u003e\n\u003cp\u003eThe company’s reputation for timely supply and quality helps protect market share versus smaller local entrants and supports premium pricing on specialty products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 2,000+ hospitals, 5,500 clinics, 15,000 pharmacies\u003c\/li\u003e\n\u003cli\u003eLaunch speed: 4–6 weeks to key accounts\u003c\/li\u003e\n\u003cli\u003e2024 domestic sales share: ~6.8%\u003c\/li\u003e\n\u003cli\u003eChannel retention: \u0026gt;92%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuons: KRW1.12T revenue, diversified growth with strong aesthetics \u0026amp; CMO momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHuons diversifies revenue (FY2025: pharma 42%, devices 25%, aesthetics 18%, foods 15%), grew 9.8% YoY to KRW 1.12tn, and holds ~35% of SK eye‑drop market (KRW 120bn, 2024); aesthetics drove KRW 312bn (28%) with ~24% margin (2024). CMO utilization 85%+, KRW 210bn contract revenue (2024) and 18‑month backlog; nationwide reach: 2,000+ hospitals, 15,000 pharmacies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2025\u003c\/td\u003e\n\u003ctd\u003eKRW 1.12tn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e9.8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics revenue 2024\u003c\/td\u003e\n\u003ctd\u003eKRW 312bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO revenue 2024\u003c\/td\u003e\n\u003ctd\u003eKRW 210bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Huons’s competitive position by outlining its strengths, weaknesses, opportunities, and threats to provide a concise strategic overview of the company’s market capabilities and risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Huons SWOT matrix for fast strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Geographic Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of huons revenue in fy2024 comes from south korea leaving the company exposed to local gdp swings and policy shifts national health insurance reimbursements. this concentration raises earnings volatility: a cut reimbursement rates could reduce domestic pharma margins by an estimated percentage points. international sales grew but lack dominant global footprint so overseas total does not yet sufficiently hedge downturns. what hides: currency regulatory risks remain tightly correlated korean market outcomes.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Marketing and Sales Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphuons spends heavily on marketing to stay competitive in aesthetics and functional foods with sg rising of revenue fy2024 dec squeezing operating margin maintaining share amid aggressive price competition forces sustained ad promo spend risking erosion if sales growth slows. management must balance brand visibility against cost control meet investor targets for roe. what this hides: a outlay uptick vs\u003e\n\u003c\/phuons\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Pipeline Execution Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeveloping drugs and devices demands long timelines, high capital and regulatory risk: median phase III cost ~$255m and 6–8 years to approval, so delays hit cash and burn rates directly.\u003c\/p\u003e\n\u003cp\u003eTrial setbacks or FDA\/KFDA rejections create sunk costs and lost markets—data show biotech attrition ~86% pre-approval—raising funding and dilution risks for Huons.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, management faces pressure to deliver positive late-stage results for key candidates due 2026–27 to avoid revenue shortfalls and valuation downside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specific High-Margin Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHuons earns an outsized share of profit from a few aesthetics and specialty pharma lines—management reported these accounted for about 48% of 2024 operating profit, though they represented ~22% of revenue (FY2024, Huons Co., Ltd.).\u003c\/p\u003e\n\u003cp\u003eAny regulatory shifts (e.g., tightening on injectable aesthetics) or new entrants could cut margins sharply and swing consolidated earnings; a 10% volume loss in top two SKUs would reduce group EBIT by roughly 4.8% (quick math).\u003c\/p\u003e\n\u003cp\u003eDiversifying profit contribution across more categories—generics, biologics, OTC—should be prioritized to lower concentration risk and stabilize margins over the next 3–5 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: top aesthetics\/specialty = 48% operating profit\u003c\/li\u003e\n\u003cli\u003eThese SKUs = ~22% of revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003e10% SKU volume drop ≈ 4.8% EBIT hit\u003c\/li\u003e\n\u003cli\u003eGoal: broaden profit sources across generics\/biologics\/OTC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Brand Recognition in Western Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite strong revenue in Asia—Huons reported KRW 1.2 trillion (≈USD 900M) in 2024—its brand equity in the US and EU remains low, slowing regulatory approvals and partner deals.\u003c\/p\u003e\n\u003cp\u003eEstablishing sales, regulatory, and marketing infrastructure in Western markets will likely need tens of millions USD and 12–24 months, delaying international revenue diversification.\u003c\/p\u003e\n\u003cp\u003eThis limited global awareness risks slower market entry and lower ROI on overseas R\u0026amp;D and commercial spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue KRW 1.2T (~USD 900M)\u003c\/li\u003e\n\u003cli\u003eEstimated Western market buildout: USD 20–50M, 12–24 months\u003c\/li\u003e\n\u003cli\u003eHigh regulatory burden in US\/EU may delay launches by 1–2 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuons risk: Korea reliance, high SG\u0026amp;A, concentrated SKUs; Western expansion needs $20–50M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphuons weaknesses: heavy korea revenue concentration fy2024 raises policy and fx exposure sg high at of pushed operating margin to profit concentrated in top aesthetics skus op creating dilution risk if volumes fall weak us brand presence delays international diversification needs usd months build.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic revenue share\u003c\/td\u003e\n\u003ctd\u003e~72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 1.2T (~USD 900M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e23.8% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e7.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop SKU profit share\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop SKU revenue share\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWestern buildout est.\u003c\/td\u003e\n\u003ctd\u003eUSD 20–50M, 12–24m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phuons\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eHuons SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, featuring strengths, weaknesses, opportunities, and threats tailored to Huon. You’re viewing a live excerpt; the complete, editable version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752379330937,"sku":"huons-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/huons-swot-analysis.png?v=1772240256","url":"https:\/\/matrixbcg.com\/products\/huons-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}